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Cytokine signaling: Inhibitors keep cytokines in check
Panu E. Kovanen and Warren J. Leonard
Some members of the CIS/SOCS/JAB/SSI family have
been demonstrated to be cytokine-inducible inhibitors
of cytokine signaling. Steps have now been made
towards clarifying the biological function of two of these
proteins, revealing that these inhibitors are essential for
the correct maintenance of cytokine signaling.
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Most mammalian cell types express a wide variety of
cytokine receptors at the cell surface. These receptors
translate and transduce various signals from the external
environment to the interior of the cell to generate the
appropriate response. The last five years have been a period
of remarkable progress in elucidating the biochemistry of
cytokine signaling. The discovery and characterization of
Janus kinases (JAKs) that bind to cytokine receptors and
phosphorylate signal transducers and activators of transcrip-
tion (STATs) has been of particular importance. The
JAK–STAT pathway is an integral component of signaling
by many cytokines. Significant progress has also been made
in understanding the importance of the correct regulation of
this signaling pathway. In addition to the role of phos-
phatases, such as Shp1 and Shp2 [1], in the downregulation
of cytokine signaling, a considerable amount of attention
has been focused on a set of proteins that include cytokine-
inducible signaling inhibitors. This family of proteins was
last reviewed in Current Biology in 1997 [2]. Since then, sig-
nificant new information regarding the specific roles of
certain members of this family of inhibitors has been gained
from studies on transgenic and knockout mice [3–8].
The prototype member of this family, cloned back in 1995
[9], was denoted CIS, for cytokine-inducible Src homol-
ogy 2 (SH2)-domain-containing protein. This protein was
identified as an immediate-early gene whose expression
was induced by interleukin-2 (IL-2), IL-3, and erythropoi-
etin. CIS (now also denoted as CIS1) was demonstrated
initially to associate with the erythropoietin receptor and
the β chain of the IL-3 receptor [9]. It has subsequently
been shown to also be able to associate with the common
β chain, βc, of the receptors for IL-3, IL-5, and granulo-
cyte–macrophage colony-stimulating factor (GM-CSF),
and the IL-2 receptor β chain [10]. CIS1 can negatively
regulate signaling by these cytokines in cell lines [9,10] as
well as in transgenic mice [8]. Interestingly, expression of
the CIS1 gene is regulated by Stat5 proteins, which them-
selves are activated by IL-2, IL-3, and erythropoietin.
Thus, CIS1 appears to represent a component of a nega-
tive-feedback loop in cytokine signaling. 
Two years ago, three groups used different experimental
approaches to clone a cytokine-inducible protein that
inhibited the actions of IL-6 and leukemia inhibitory factor
[11–13]. This new protein was variably denoted as SOCS-1
(suppressor of cytokine signaling-1), JAB (JAK-binding
protein), or SSI-1 (STAT-induced STAT-inhibitor-1) pro-
teins. Two other structurally related proteins were also
identified (SOCS-2 and SOCS-3) at the same time. Like
CIS1, all three of these proteins contain an SH2 domain
as well as other regions of homology [2]. Thus, the
CIS/SOCS/JAB/SSI family was recognized to exist [2]. The
nomenclature for this family of proteins was then, and still
is, confusing. In addition to the SOCS nomenclature
(where the hyphen has now been lost so that SOCS-1 is
denoted as SOCS1), the CIS, JAB, and SSI-1 nomencla-
tures are still used. 
In reality, none of the names is necessarily completely
appropriate. Firstly, a range of proteins have been identi-
fied to have homology to a carboxy-terminal motif of
CIS/SOCS1/JAB/SSI-1, termed the SOCS box. Although
some of these proteins contain SH2 domains, others
instead contain WD40 repeats, SPRY domains, ankyrin
repeats or GTPase domains (Table 1) [14]. Thus, the CIS
nomenclature does not accurately encompass all of these
proteins; moreover, not all of these proteins have been
shown to be cytokine inducible. Secondly, it is not yet
clear whether all of these proteins suppress cytokine sig-
naling or whether all are STAT inhibitors; therefore, the
SOCS and SSI nomenclature may not be completely
appropriate either. Finally, although JAB associates with
JAKs, CIS1 does not, so the ability to interact with JAKs is
also not a universal feature of these proteins. For the
purpose of this article, however, we will focus only on
those proteins that contain a central SH2 domain and a
carboxy-terminal SOCS box (see Table 1).
As noted above, since their cloning the CIS/SOCS/JAB/SSI
proteins have been linked to the negative regulation of
a number of cytokines. Some of these proteins, such as
SOCS1/JAB/SSI-1, SOCS3/CIS3/SSI-3, and CIS1, are
induced by many different cytokines [2], and their induc-
tion seems to be dependent on STATs. The mechanism by
which these proteins inhibit cytokine signaling is not fully
understood. SOCS1/JAB/SSI-1 and SOCS3/CIS3/SSI-3
associate with JAKs and inhibit their activity, thus providing
a possible explanation for their inhibitory action [15,16]. In
contrast, CIS1 associates with receptors but does not bind
JAKs. Figure 1 depicts SOCS1/JAB/SSI-1 associating with
JAKs and CIS1 with cytokine receptor chains. The CIS1
SH2 domain is essential for the inhibitory action of CIS1,
but the protein(s) that interacts with this domain remains
unclear [10]. For SOCS1/JAB/SSI-1, the region amino-ter-
minal to the SH2 domain is clearly required for efficient
binding to JAKs and for the function of the protein
[15,17,18]. The function of the SOCS box is currently not
known, although it does not appear to be required for inhi-
bition of Jak2 activity by SOCS1/JAB/SSI-1 and instead
may regulate the stability of the protein [17,19,20]. This
putative function of the SOCS box involves an interaction
with elongins B and C, but it has not yet been resolved
whether this interaction results in increased or decreased
protein stability [19,20].
Most of the data linking CIS/SOCS/JAB/SSI proteins to
the negative regulation of cytokine signaling have been
obtained from overexpression models. Although these
systems provide valuable information, they cannot
provide a clear understanding of whether a given protein
is required for a biological action in vivo. The initial analy-
sis of mice deficient in SOCS1/JAB/SSI-1, which we shall
term SOCS1 in the remainder of the review, revealed an
essential role for SOCS1 in vivo [3,4]. Mice lacking
SOCS1 exhibited post-natal death that was associated
with growth retardation, liver degeneration and necrosis,
and lymphoid abnormalities that included diminished cel-
lularity of the thymus and loss of B lymphocytes. This
phenotype was surprising, because it was not clearly
attributable to an amplified cytokine response, as one
might have expected. In addition, these mice showed no
signs of generalized inflammation, which might have been
expected, given that this phenotype is observed in mice
deficient in Shp1 [21], a phosphatase that also inhibits the
action of certain cytokines.
The changes observed in SOCS1-deficient mice may have
been caused by the loss of a function(s) of SOCS1 that is
not necessarily directly related to augmented cytokine sig-
naling, but instead might relate to effects on apoptosis. In
fact, lymphocytes from these mice were observed to have a
significantly accelerated rate of apoptosis that correlated
with increased expression of the pro-apoptotic Bcl-2-family
member Bax [3]. Nevertheless, it was clear that cytokine
signaling in SOCS1 knockout mice was also abnormal,
because thymocytes from the mice were hyper-responsive
to the combination of triggering of the T-cell receptor and
treatment with IL-2 or IL-4, indicating that the responsive-
ness of T cells to at least these cytokines was altered [3].
Consistent with this observation, constitutive Stat1 activity
was observed in the liver tissue of SOCS1-deficient mice
[4], suggesting enhanced signaling by cytokines that acti-
vate Stat1, such as interferon γ (IFNγ) or IL-6.
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Table 1
SOCS-family proteins with SH2 domains.
Name Induced by Biological effect Possible mechanism of action
CIS1 IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-12, IL-13, Suppresses signaling by Binds to phosphorylated
LIF, GM-CSF, G-CSF, M-CSF, EPO, TPO, IL-2, IL-3, EPO, growth hormone, cytokine receptors; inhibits
IFNγ, growth hormone, TNFα, prolactin, leptin prolactin STAT activation and STAT-
dependent transcription
SOCS1/ IL-2, IL-3, IL-6, IL-13, LIF, Suppresses signaling by Inhibition of JAK activity by
JAB/SSI-1 GM-CSF, IFNγ, growth hormone, IL-2, IL-3, IL-4, IL-6, growth hormone, binding to the kinase activation
SCF, prolactin LIF, prolactin, IFNγ, EPO loop; inhibition of STAT
activation and STAT-
dependent transcription
SOCS2/ IL-1, IL-3, IL-4, IL-6, LIF, GM-CSF, Function unknown Unknown
CIS2/SSI-2 G-CSF, EPO, IFNγ,
growth hormone, prolactin
SOCS3/ IL-1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-10, Suppresses signaling by Inhibition of JAK activity;
CIS3/SSI-3 IL-11, IL-12, IL-13, IFNγ, LIF, G-CSF, IL-2, IL-3, IL-11, growth hormone, inhibition of STAT
EPO, TPO, leptin, prolactin, LIF, leptin, prolactin, EPO, IFNγ activation and STAT-
growth hormone, TNFα, GM-CSF dependent transcription
SOCS4–7/ Unknown Function unknown Unknown 
CIS4–7/SSI-4–7
Other proteins containing the SOCS box motif but which do not contain
an SH2 domain have been described and are detailed in [14]. These
include proteins containing SPRY domains, SSB-1, SSB-2, SSB-3;
those containing GTPase domains, retinoic acid receptor (RAR), RAR-
LIKE; those containing WD40 repeats, WSB-1, WSB-2; and those
containing ankyrin repeats, ASB-1, ASB-2, ASB-3. LIF, leukemia
inhibitory factor; GM-CSF, granulocyte–macrophage colony-stimulating
factor; G-CSF, granulocyte colony-stimulating factor; M-CSF,
macrophage colony-stimulating factor; EPO, erythropoietin; TPO,
thrombopoietin; SCF, stem cell factor; TNFα, tumor necrosis factor α.
In a recent issue of Cell, two reports [5,6] have clarified
several of the issues raised by the original reports describ-
ing SOCS1-deficient mice. Both studies demonstrate that
the major phenotypic abnormalities observed in these
mice are, in fact, caused by alterations in cytokine signal-
ing. In particular, these papers reveal that IFNγ is an
essential mediator of the pathological changes in the mice.
Interestingly, in neonatal mice, injections of IFNγ induce
pathological changes similar to those observed in SOCS1
knockout mice [22]. Moreover, constitutive expression of
IFNγ in transgenic mice causes hematological and
immunological changes similar to those observed in mice
deficient in SOCS1, with B cells being particularly sensi-
tive to the toxic effects of IFNγ [23,24].
Other studies have shown not only that IFNγ can induce
SOCS1 expression, but also that SOCS1 can inhibit IFNγ
signaling [5,25,26], suggesting that SOCS1 is part of a neg-
ative-feedback loop regulating IFNγ signaling. Indeed,
whereas IFNγ injections in neonatal mice cause similar
pathological effects to those seen in SOCS1-deficient
mice, administration of a neutralizing anti-IFNγ antibody
to these mice prevents these pathological changes [5]. Fur-
thermore, the mice are highly resistant to infection with
Semliki forest virus, an anti-viral response that is depen-
dent on IFNγ activity. In addition, SOCS1-deficient mice
show a more than 100-fold increase in the level of IFNγ-
dependent killing of Leishmania major by macrophages.
Finally, mice deficient in both SOCS1 and IFNγ do not
exhibit the multi-organ pathology seen in mice deficient in
SOCS1 alone, thus proving the essential role of IFNγ in
mediating toxicity in SOCS1-deficient mice. 
Because activated T cells are rich sources of IFNγ, the
effects of the lack of SOCS1 expression were also ana-
lyzed in mice that do not produce T or B lymphocytes due
to the absence of the recombination-activating gene RAG2
[6]. Interestingly, the resulting mice do not exhibit the
phenotypic abnormalities seen in mice that lack SOCS1
expression alone, indicating that the pathological changes
are mediated by lymphocytes, presumably T lympho-
cytes, because B lymphocytes do not produce significant
amounts of IFNγ. Similar observations are made when the
hematopoietic system of Jak3-deficient mice, which are
significantly deficient in all lymphoid cells, is reconsti-
tuted with bone marrow from SOCS1-deficient mice.
Together, these results demonstrate that lymphocytes are
required for the abnormalities seen in SOCS1 knockout
mice, at least in part because of their production of IFNγ. 
What might be the cause of this excessive IFNγ produc-
tion? One possibility is that T-lymphocyte function in
general is abnormal in these mice. This is supported by
the finding that peripheral T cells from these mice exhibit
an ‘activated’ phenotype [6], a finding consistent with the
hyper-responsiveness of these cells to IL-2 and IL-4 [3].
Thus, the absence of SOCS1 may lead to amplified
responses to a number of cytokines. This, in turn, may
result in aberrant T-lymphocyte activation and abnormal
IFNγ production, finally culminating in the observed
pathological effects. 
The role of SOCS3 in vivo has also been analyzed. Mice
expressing a SOCS3 transgene as well as mice deficient in
SOCS3 have been generated and the analysis of these mice
revealed that SOCS3 expression is essential for regulating
fetal erythropoiesis [7]. SOCS3 overexpression completely
blocks fetal erythropoiesis, whereas SOCS3-deficient
embryos show increased erythrocytosis, and neither SOCS3
transgenic or knockout embryos are viable. A temporal
comparison of SOCS3 expression and fetal erythropoiesis is
consistent with negative regulation of erythropoietin signal-
ing by SOCS3. In support of this, the phenotype of SOCS3
transgenic mice closely resembles that of mice lacking
expression of Jak2 or the erythropoietin receptor [27–29]. It
is noteworthy that the expression of SOCS1 and  SOCS3
seems to be developmentally regulated. It will be most
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Figure 1
Schematic of cytokine signaling, showing that CIS1 is regulated by
STAT and is an inhibitor of STAT activation. Whereas CIS1 associates
































interesting to clarify the mechanism behind the coordinated
expression of SOCS proteins, as well as the precise roles of
these proteins during development.
Thus, although CIS/SOCS/JAB/SSI proteins were recog-
nized as inhibitors of cytokine signaling back in 1997, at that
stage the field was in its infancy in terms of understanding
which of these inhibitors was most important for which par-
ticular cytokines. Although much remains to be learned, the
murine models have now clarified our understanding of the
essential roles for SOCS1 and SOCS3 in vivo.
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